Enhancing immune response in melanoma treatment
Official title: Targeting dsRNA sensing and ADAR1 in melanoma
Funded at Yale University · NIH-11042275 · Data updated 2026-11-12
This study is looking for better ways to help your immune system fight melanoma by targeting certain receptors and blocking a protein that can hold back your body's natural defenses, with the hope of making current treatments work even better for you.
Quick facts
| Grant type | R37 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Yale University NIH-funded |
| Lab location | 1 site (New Haven, United States) |
| Project start | March 1, 2024 |
| Project end | February 28, 2029 |
| Funding year | 2025 |
| Award (this year) | $631,778 |
| NIH project number | 5R37CA279834-02 |
| Project ID | NIH-11042275 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients with melanoma who have not responded well to current immunotherapy treatments.
✕Less likely to help
Patients with early-stage melanoma or those who have not yet undergone immunotherapy may not benefit from this research.
What this research studies
This research investigates ways to improve the effectiveness of melanoma treatments by enhancing the body's immune response. It focuses on targeting specific receptors that recognize double-stranded RNA (dsRNA) and inhibiting a protein called ADAR1, which can limit anti-cancer immunity. By using these strategies, the researchers aim to make melanoma tumors more responsive to existing immunotherapies, potentially leading to better outcomes for patients. The study will explore the best combinations of these approaches to maximize their effectiveness in treating melanoma.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for melanoma, improving survival rates and quality of life for patients.
How similar studies have gone: Previous research has shown promising results in enhancing anti-tumor immunity through similar approaches, indicating potential for success in this study.
Where this research is happening
-
Yale University
New Haven, United States Active
Researchers
- Principal investigator: Ishizuka, Jeffrey J. — Yale University
- Study coordinator: Ishizuka, Jeffrey J.
Related research
Other NIH-funded projects on the same topics.
-
Melanoma vaccine built from tiny spherical nucleic acids
A new kind of cancer vaccine using tiny spherical nucleic acids to help the immune system fight advanced melanoma.
-
Injecting immune-boosting medicine into melanoma tumors to help the immune system reject them
This gives an immune-boosting drug directly into melanoma tumors in pet dogs to help their T cells find and destroy the cancer.
-
SIRT6 and melanoma growth and spread
Researchers are seeing if blocking a protein called SIRT6 can help stop melanoma from growing and spreading in people with melanoma.
-
How tumor cell stress and nearby support cells help melanoma spread
This project looks at whether blocking a tumor cell stress response and changing how nearby support cells behave might keep melanoma cells from surviving, spreading, and resisting treatment.
-
PLK4 as a potential drug target in melanoma
Researchers are exploring whether blocking PLK4 could be a new way to treat melanoma and how PLK4 works with other melanoma-driving pathways.
-
A new lentivector to deliver multiple TCRs for melanoma cell therapy
A new gene-delivery approach aims to boost T cell receptors inside patients’ own cells to treat advanced melanoma.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.